Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Colonic Neoplasms 7Colorectal Neoplasms 6Rectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Liver Neoplasms 2Head and Neck Neoplasms 2Hand-Foot Syndrome 2Adenomatous Polyposis Coli 2Smoking 1Pancreatic Neoplasms 1Pain, Postoperative 1Pain 1Nasopharyngeal Carcinoma 1Lymphoma, Follicular 1Lung Neoplasms 1Influenza, Human 1Drug-Related Side Effects and Adverse Reactions 1Breast Neoplasms, Male 1Agnosia 1Adenocarcinoma of Lung 1

Interventions

Cisplatin 51Gemcitabine 28Radiotherapy, Intensity-Modulated 26Capecitabine 19Docetaxel 16toripalimab 12Fluorouracil 11Radiotherapy 9Drug Therapy 8nedaplatin 6camrelizumab 6Induction Chemotherapy 5spartalizumab 4nimotuzumab 4Neoadjuvant Therapy 4Carboplatin 4tislelizumab 3Immune Checkpoint Inhibitors 3Chemoradiotherapy 3sintilimab 2cisplatin-guanosine adduct 2apatinib 2SSRP1 protein, human 2Radiation 2Injections 2Endostatins 2CF regimen 2streptococcal preparation 722 1penpulimab 1lobaplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Nasopharyngeal Carcinoma × Celecoxib × Clear all
NCT02537925 2015-09-02

The Effect of COX-2 Inhibitor on Radiosensitivity in Nasopharyngeal Carcinoma

Nanning Second People's Hospital

Phase 3 Unknown
120 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡